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ABSTRACT 
Gamma-hydroxybutyrate (GHB) is a GHB-/GABAB-receptor agonist. Reports from GHB abusers 
indicate euphoric, prosocial, and empathogenic effects of the drug. We measured the effects of GHB 
on mood, prosocial behavior, social and non-social cognition and assessed potential underlying 
neuroendocrine mechanisms. GHB (20 mg/kg) was tested in 16 healthy males, using a randomized, 
placebo-controlled, cross-over design. Subjective effects on mood were assessed by visual-analogue-
scales and the GHB-Specific-Questionnaire. Prosocial behavior was examined by the Charity Donation 
Task, the Social Value Orientation test, and the Reciprocity Task. Reaction time, memory, empathy, 
and theory-of-mind were also tested. Blood plasma levels of GHB, oxytocin, testosterone, 
progesterone, dehydroepiandrosterone (DHEA), cortisol, aldosterone, and adrenocorticotropic-
hormone (ACTH) were determined. GHB showed stimulating and sedating effects, and elicited 
euphoria, disinhibition, and enhanced vitality. In participants with low prosociality, the drug 
increased donations and prosocial money distributions. In contrast, social cognitive abilities such as 
emotion recognition, empathy, and theory-of-mind, and basal cognitive functions were not affected. 
GHB increased plasma progesterone, while oxytocin and testosterone, cortisol, aldosterone, DHEA, 
and ACTH levels remained unaffected. GHB has mood-enhancing and prosocial effects without 
affecting social hormones such as oxytocin and testosterone. These data suggest a potential 
involvement of GHB-/GABAB-receptors and progesterone in mood and prosocial behavior. 
 
Key Words: sodium oxybate, gamma-hydroxybutyric acid, club drug, altruism, fairness, rape drug 
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1. INTRODUCTION 
Gamma-hydroxybutyrate (GHB) is an endogenous short-chain fatty acid neuromodulator which is 
biosynthetically derived from the major inhibitory neurotransmitter gamma-aminobutyrate (GABA) 
(Bessman and Fishbein, 1963). It appears to bind to specific GHB- and GABAB-receptors (Snead, 
2000). A potent interaction of GHB with extrasynaptic α4βδ GABAA receptors suggested previously 
has recently been challenged (Connelly et al., 2013). While physiological concentrations of GHB seem 
to be insufficient to stimulate GABAB receptors, this mechanism is discussed to be responsible for its 
psychotropic effects when administered orally (Andresen et al., 2011). Although the physiological 
role of endogenous GHB is still unclear, some evidence points to an anti-apoptotic activity (Wendt et 
al., 2014). Apart from its direct effects on GHB- and GABAB-receptors, GHB has neuromodulatory 
properties on glutamate, dopamine, serotonin, norepinephrine, and cholinergic transmission 
(Andresen et al., 2011). Clinically, GHB is internationally registered for the treatment of narcolepsy, 
and in some European countries for the treatment of alcohol withdrawal and craving (Keating, 2014). 
Moreover, it was recently proposed as an experimental therapeutic in depression (Bosch et al., 
2012). 
 
GHB abusers report enhancing effects on sociability and mood (Sumnall et al., 2008), whereby the 
drug has gained some notoriety as a “club drug” used by a small but growing part of the population 
(Carter et al., 2009). In some aspects, the acute effects of GHB resemble the entactogenic effects (i.e. 
feelings of closeness, desire for physical contact) of 3,4-methylenedioxymethamphetamine (MDMA, 
ecstasy), which has stimulated its most widespread street name “liquid ecstasy” (Uys and Niesink, 
2005). MDMA is known to enhance emotional empathy and prosocial behavior (Bedi et al., 2010; 
Hysek et al., 2014), which was paralleled by increased oxytocin plasma levels (Schmid et al., 2014). 
Additionally to the MDMA-like entactogenic effects, GHB was reported to enhance sexually connoted 
affiliative behavior (Lee and Levounis, 2008), indicating an involvement of more neuroendocrine 
mechanisms than the oxytoninergic pathway. GHB is known to affect levels of several steroidal 
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hormones such as neurosteroids and cortisol in animals and humans (Bosch et al., 2012), and GABA-B 
receptors are discussed in the regulation of testosterone secretion (Amikishieva, 2007). Testosterone 
is a sex steroid hormone which is known to play an important role in human social interaction 
(Eisenegger et al., 2010; Bos et al., 2012). Taking these evidences together, the androgen system with 
the primary hormone testosterone and its precursor dehydroepiandrosterone (DHEA) seems another 
plausible candidate neuroendocrine mechanism of the prosocial effects of GHB. 
 
Anxiolytic and stress reducing effects are attributed to neurosteroids such as progesterone, 
tetrahydroprogesterone (3α,5α-THP), and tetrahydrodeoxycorticosterone (THDOC), whose syntheses 
are promoted by GHB in animals (Barbaccia et al., 2002). Moreover, animal and human data show 
that progesterone release mirrors an individual`s level of social-affiliative motivation (Maner et al., 
2010). Also, hypothalamic-pituitary-adrenal (HPA-) axis activity was bidirectionally altered by the 
drug (Van Cauter et al., 1997; Nava et al., 2007), and it was shown that stress influences social 
interactions (Tomova et al., 2014). Consequently GHB might elicit its social effects either directly via 
GHB/GABA receptors or indirectly by increasing plasma levels of hormones such as oxytocin and 
testosterone, by altering neurosteroidogenesis or through the modulation of the HPA-axis. 
 
In order to characterize the acute effects of GHB on prosocial behavior, social cognition, and mood, 
we assessed a social decision-making and social cognition test battery, as well as subjective mood 
ratings in a randomized, placebo-controlled, balanced, cross-over design in 16 healthy males. We 
decided to focus on male individuals to reduce variance due to steroid hormone fluctuations during 
menstrual cycle. Potential neuroendocrine parameters mediating GHB effects were investigated by 
determination of plasma time-courses of oxytocin, testosterone, DHEA, progesterone, and stress 
hormones such as cortisol, aldosterone, and adrenocorticotropic hormone (ACTH). We hypothesized 
that GHB enhances mood, emotional empathy, and prosocial behavior, while increasing plasma 
levels of oxytocin, testosterone, and progesterone and altering HPA axis activity. 
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2. METHODS AND MATERIALS 
2.1 Participants 
Sixteen healthy, male, and non-smoking participants with mean age of 23.9 years (±2.9 SD, range 19-
29), a mean verbal intelligence quotient (IQ) of 104.2 (±14.6 SD, range 86-145), and a mean weight of 
74.4 kg (±8.2 SD, range 60.4-87.0) participated in the study. Exclusion criteria were any Axis-I DSM-IV 
psychiatric disorder, any form of addiction or regular illegal drug use (lifetime use >5 occasions) with 
exception of occasional cannabis use, a lifetime history of GHB use, a neurological disorder or head 
injury, clinically relevant medical diseases, a family history of schizophrenia or bipolar disorder, and 
any use of prescription drugs. All participants had to abstain from caffeine on the study days and 
from alcohol for at least 24 hours before the experiments. In order to ensure drug abstinence on the 
test days, a urine screening was done using a Dimension RXL Max (Siemens, Erlangen, Germany) 
immunoassay. The study was approved by the Cantonal Ethics Committee of Zurich and by 
Swissmedic and registered at ClinicalTrials.gov (NCT02342366). All participants gave written 
informed consent according to the Declaration of Helsinki and were compensated for their 
participation. 
 
2.2 Procedure 
The study design consisted of four sessions: screening session, experimental day I, experimental day 
II, and follow-up session, all separated by an interval of seven days. We used a randomized, double-
blind, placebo-controlled, and balanced cross-over design. A trained psychiatrist carried out a 
Structured Clinical Interview for DSM-IV Axis-I Disorders during the screening session. We assessed 
drug use with the Interview for Psychotropic Drug Consumption (Quednow et al., 2004). Subjects also 
performed the Mehrfachwahl-Wortschatz-Intelligenztest (Lehrl, 2005), a standardized German 
vocabulary test, in order to estimate potential premorbid verbal IQ. Finally, in the screening session 
subjects performed a brief neuropsychological test battery to assure normal cognitive functions (data 
not shown). On the experimental days a peripheral venous catheter for blood sampling was placed at 
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8:30am, and GHB (Xyrem® solution; 20 mg/kg in juice) or placebo (salted juice) was given orally at 
9:00am. Each experimental session lasted for 225min (Supplementary Figure 1). Subjects had to be 
fasting during the morning of the experiments. At the follow-up session, the neuropsychological test 
battery of the screening session was repeated (data will be published elsewhere). 
 
2.3 Measures 
2.3.1 Subjective Effects 
For the measurement of acute subjective drug effects we used four Visual Analogue Scales (VAS) 
assessing the general drug effect, sedation, stimulation, and dizziness at the time points t-
15,+40,+60,+100,+120, and+180min, as well as a GHB Specific Questionnaire (GSQ)(Kim et al., 2008) 
at t-17,+38,+66,+104,+138,+198min. The GSQ consists of 15 sensory-motor and cognitive items 
measuring involuntary muscle jerking, silliness, happiness, loss of memory or amnesia, acoustic 
hallucinations, increased sexuality, visual hallucinations, tendency to talk, disinhibition, heightened 
sense of touch, increased sensitivity to sound, stimulation, euphoria, and vitality. Subjects rate the 
occurrence/intensity of each item via five scales, ranging from 0-4 (“not present” to “strong”). 
 
2.3.2 Charity Donation Task 
Subjects performed a computer-based Charity Donation Task (CDT, adapted from Hare et al. [2010)]) 
at t+70min. Subjects were asked to read a description of 10 charities (Supplementary Table 1), and 
were then informed that they could donate 0-40 Swiss Francs (CHF) from their study compensation 
to one of the listed charities. Finally, subjects were asked to rate on a 7-point rating scale (“not at all” 
to “very much”), how much the charity deserved the donation, and how much pleasure the subject 
felt about having donated. 
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2.3.3 Social Value Orientation 
The Social Value Orientation (SVO) test was implemented at t+90min. It is a paper-based, resource 
allocation test to assess social behavior (Murphy et al., 2011). The subjects were instructed to choose 
their favorite joint distribution between themselves and another person, from six primary and nine 
secondary SVO slider items with a resource allocation choice over a defined continuum of joint 
payoffs. The subjects were told that two of their choices would be randomly selected, and that funds 
would be shared according to these choices. Prosocial behavior – defined as maximizing the total of 
resources for the self and others and minimizing the difference between the two – is indicated by the 
wideness of the SVO angle, which increases when subjects maximized the allocation for the others. 
For the calculation of the SVO angle please see the Supplementary Material.  
 
2.3.4 Reciprocity Task  
To investigate effects of GHB on subjects´ positive reciprocity, i.e. their tendency to respond to a 
positive action with another positive action, we administered a Reciprocity Task at t+160min. This 
computer-based, simulated task is similar to the Trust Game (Evans and Krueger, 2011). After the 
decision-making phase, subjects had to rate the amount of pleasure they felt related to their 
decisions. For details please see Supplementary Material. 
 
2.3.5 Multifaceted Empathy Task 
Participants performed the Multifaceted Empathy Task (MET) at t+75 min. This computer test 
comprises 40 photographs of people in emotionally charged situations (Dziobek et al., 2008), and has 
been described in detail elsewhere (Preller et al., 2014). The stimuli depict everyday life situations 
conveying information on emotional mental states via facial expression, body language, and context. 
Via distinct questions, which are answered on visual analogue scales, cognitive empathy (CE), explicit 
emotional empathy (EEE), and implicit emotional empathy (IEE) are measured (for details see 
Supplementary Material). 
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2.3.6 Movie for the Assessment of Social Cognition 
The Movie for the Assessment of Social Cognition (MASC) is an ecologically valid, video-based test of 
social cognition (Dziobek et al., 2006), which we implemented at t+105min. It has also been 
described in detail elsewhere (Preller et al., 2014). Participants had to watch a 15-min movie and 
make inferences about the video characters’ mental states requiring the understanding of emotions, 
thoughts, and intentions, and concepts such as false belief, faux pas, metaphor, and sarcasm in an 
everyday-life situation, which are measured by Theory-of-Mind-related multiple-choice questions 
(for details see Supplementary Material).  
 
2.3.7 Cognitive Tests 
To study acute GHB effects on visual working memory and reaction time subjects had to perform the 
Delayed Matching to Sample (DMS, t+28min) and the Reaction Time (RTI, t+52min) tests from the 
Cambridge Neuropsychological Test Automated Battery (CANTAB, Cambridge Cognition, Cambridge, 
UK). In order to assess immediate (t+25min) and delayed verbal recall (t+57min), we employed a 
shortened German version of the Rey Auditory Verbal Learning Test (RAVLT) (Helmstaedter et al., 
2001), as GHB has a short half-life of 45min (Abanades et al., 2006). Details of these tasks are 
reported in the Supplementary Material. 
 
2.3.8 Endocrine Parameters and Pharmacokinetics of GHB  
We performed blood sampling at -20,+35,+60,+100,+135, and+190min to generate plasma. We 
determined plasma concentrations of GHB using gas chromatography-mass spectrometry (GC-MS) 
according to Meyer et al. (2011) with some modifications; and testosterone, progesterone, DHEA, 
cortisol, and aldosterone using liquid chromatography-mass spectrometry (LC-MS/MS) according to 
(Gachet et al., 2014). Oxytocin levels were measured according to procedures established previously 
(Neumann et al., 2013). For details see Supplementary Material. 
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2.4 Statistical Analysis 
All data were analyzed using SPSS® 22.0 for Windows. GHB and hormone plasma levels were plotted 
against time and areas under the curve (AUC) were calculated using the trapezoid rule. Demographic 
and neuropsychological test data were analyzed by paired t-tests. For the analyses of VAS and GSQ 
scales as well as GHB and hormone plasma levels, repeated measures ANOVA with drug (2-fold: GHB 
vs. placebo) and time (GSQ items: 3-fold; oxytocin and ACTH: 4-fold; VAS scales, GHB, and all other 
hormones: 6-fold) as within-subject factors were applied. Greenhouse-Geisser correction and 
adjusted p-values were used in models with more than one degree of freedom in the numerator. 
Paired t-tests were applied for post hoc treatment comparisons (placebo vs. GHB). All confirmatory 
statistical comparisons were carried out at a significance level of p<.05 (two-tailed). Finally, because 
of the small sample size, Spearman’s rho was used for correlation analysis. Here, the significance 
level was set at p<.01 (two-tailed) to avoid accumulation of alpha-error. 
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3. RESULTS 
3.1 GHB plasma levels and subjective effects measured by VAS 
GHB reached peak plasma concentration at t+35 min and dropped back to close to the physiological 
level at t+190min (Fig. 1a). A drug*time (2*6) ANOVA showed significant main effects for drug 
(F(1,15)=104.0, p<10-7), time (F(5,11)=55.9, p<10-7), and a significant drug*time interaction 
(F(5,11)=55.7, p<10-7), reflecting supraphysiological GHB levels after GHB intake and the time-course 
of the pharmacokinetic of the drug. 
Under GHB, the general drug and sedative effects peaked at t+40min and vanished at 180min post 
intake (Fig. 1b,c). Interestingly, subjects rated the effect of GHB as sedating and stimulating at the 
same time (Fig. 1c,d). Stimulation and dizziness induced by GHB peaked at t+40min but reached 
placebo levels already at t+100min (Fig. 1d,e). In drug*time (2*6) ANOVAs, all four VAS scales 
showed significant time effects (F(5,11)=10.4-21.5, p <.0001). With exception of the stimulation scale 
all other scales revealed significant drug effects (F(1,15)=4.0-7.3, p<.05) and significant drug*time 
interactions (F(5,11)=3.4-7.2, p<.05-.01).  
 
- Figure 1 about here - 
 
 
3.2 GHB Specific Questionnaire (GSQ) 
Drug*time (2*6) ANOVAs revealed significant drug*time interactions for the items disinhibition, 
euphoria, and the tendency to talk (F(5,11)=3.3-7.7, p<.05-.01), a significant drug effect for the item 
vitality (F(1,15)=9.0, p <.01)(Fig. 2a-c), and significant time effects for disinhibition, euphoria, 
increased sexuality, silliness, happiness, tendency to talk, vitality, and increased sensitivity to sound 
(F(5,11)=3.0-15.4, p <.05 - .001)(Fig. 2a-c,Supplementary Fig. 2a-d). Taken together, 20 mg/kg GHB 
induced an affective state that resembles hypomania. 
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- Figure 2 about here - 
 
3.3 Charity Donation Task, Social Value Orientation, and Reciprocity Task 
To avoid ceiling effects, two highly prosocial subjects who already spend the maximum of 40 CHF 
under placebo and did not change under GHB were excluded from the analysis of the Charity 
Donation Task. Under GHB, subjects donated significantly more (+5.36 CHF) than under placebo 
(t(13)=-2.3, p<.05, d=0.60)(Fig. 3a). Moreover, under GHB, subjects also tended to enjoy their 
donation more (rating range 1-7 [mean±SD]: placebo: 3.1±2.7, GHB: 3.8±2.4; t(13)=-1.7, p=.11, d=.46) 
and reported that the charity deserved the donation more strongly (placebo: 3.5±2.9, GHB: 4.7±2.7; 
t(13)=-1.9, p=.08, d=.52). Pleasure of donation was positively correlated with GHB plasma 
concentration at t+100min (the task was done between t+60 and t+100min; r=.60, p<.01), indicating 
that pleasure of donation increased with GHB plasma levels. 
For the analysis of the SVO task four subjects were excluded as they displayed an SVO° of >40° in the 
placebo condition, indicating highly prosocial behavior already at baseline with little chance to be 
further enhanced. In the GHB condition subjects displayed a significantly wider SVO° compared to 
placebo (t(11)=-2.2, p<.05, d=0.62), reflecting a preference for prosocial resource allocations (Fig. 
3b).  
In the analysis of the Reciprocity Task, one highly prosocial subject spending more than 500 points 
under placebo was excluded as no further improvement was expected. Post-acutely (t+160min), GHB 
administration was associated with slightly elevated positive reciprocity but the effect was far from 
being significant (t(14)=-.60, p=.56, d=0.15) (Fig. 3c). Interestingly, under placebo the reward given to 
the other player was not significantly correlated with the feeling of pleasure when being prosocial 
(r=-.30, p=.29), whereas under GHB the reward given and the pleasure of giving were correlated (r=-
.65, p=.008)(Supplementary Fig. 3). When we considered the order of placebo and GHB 
administration in repeated measures ANOVAs with drug as within-subject factor and order as 
between-subject factor, the results remained unchanged. 
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- Figure 3 about here - 
 
3.4 Multifaceted Empathy Task and Movie for the Assessment of Social Cognition 
GHB showed no effect on cognitive and emotional empathy in the MET. Furthermore, there was no 
significant drug effect on mental perspective-taking measured with the MASC (Tab. 1). 
 
3.5 Reaction time and memory 
At this moderate dose, GHB neither affected reaction and movement time nor verbal or visual 
memory performance (Tab. 1). Thus, the prosocial effects are likely not explained by cognitive effects 
or increased motor impulsivity. 
 
3.6 Neuroendocrinology 
In order to control for potential hormonal baseline differences between test days, hormone levels 
corrected for baseline levels (t-20min) were analyzed additionally to the uncorrected values (Fig. 
4a,b; Supplementary Fig. 4). Drug*time (2*4-6) repeated measures ANOVAs revealed significant 
time effects for progesterone (Fig. 4a,b), testosterone, aldosterone, and cortisol (F(5,11)=3.7-21.7, 
p<.05-.001)(Suppl. Fig. 4c-l), reflecting well-known circadian changes of these steroids. For baseline-
corrected progesterone, we found a significant drug effect (F(1,15)=3.4, p<.05), indicating increased 
progesterone release under GHB, which was significant at+100min in the post hoc test (Fig. 4a). In 
the analysis of AUCs, baseline-corrected progesterone levels showed similar effects (here with 
moderate effect sizes), pointing to an increase of progesterone under GHB (Tab. 2). 
GHB plasma levels at+135min were correlated with progesterone change scores at 135min (r=.69, 
p<.01) and with AUC change scores (r=.73, p<.001). We did not observe any significant correlations 
between progesterone plasma levels and subjective drug effects or behavioral task performance 
within the GHB condition. We also did not observe significant effects of progesterone change scores 
[GHB minus placebo] and subjective and behavioral outcomes. Interestingly however, we found that 
low progesterone levels at baseline (t-20 min) were predictive of donation effects in the charity 
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donation task (r=-.65, p<.01) and the SVO° (r=-.65, p<.01), indicating that GHB provoked prosocial 
behavior specifically in individuals with low progesterone levels. 
 
- Figure 4 about here - 
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4. DISCUSSION 
In this study, GHB enhanced mood and induced prosocial effects in humans which were paralleled by 
increased progesterone plasma levels. Contrary to our hypothesis, GHB did neither alter empathy or 
mental perspective-taking nor plasma levels of oxytocin, testosterone, cortisol, ACTH and 
aldosterone. 
Surprisingly, the quality of subjective effects showed a simultaneous, mixed stimulating-sedating 
pattern. The sedating, stimulating, and general drug effects both peaked at 40min. While the 
stimulating effects had returned to placebo levels already after 100min, the general and sedating 
effects lasted until 180min post intake, corresponding to the time-course of GHB plasma 
concentrations. This stands in contrast to a previous study which examined much higher doses of 
GHB (40-72 mg/kg) reporting a temporally separated mixed stimulant-sedative pattern. The pattern 
was biphasic with initial stimulation (peak at minute 45 p.i.) and following sedation (peak at minute 
60-90 p.i.)(Abanades et al., 2006). In contrast, our dose induced a state with both qualities at the 
same time, albeit showing more enduring general and sedating effects compared to stimulation (Fig. 
1c,d). These differing time-courses seem attributable to divergent dose-dependent receptor 
activation patterns. It has been suggested that lower doses disinhibit thalamocortical neurons and 
neurons in the ventral tegmental area (VTA) via agonism at presynaptic GABAB receptors and 
simultaneously inhibit these neurons via postsynaptic GABAB receptors, while higher doses 
additionally involve G protein-gated inwardly rectifying potassium (GIRK) channels, leading to a 
delayed and more intense neuronal hyperpolarization (Luscher and Slesinger, 2010). Consequently, 
simultaneous stimulating and sedating effects would be expected at lower doses, while a dissociation 
of these effects with increased sedation at later time points would be expected at higher doses of the 
drug. 
 
GHB enhanced mood in our subjects, eliciting an affective state that resembled hypomania, including 
disinhibition, euphoria, increased vitality, and enhanced tendency to talk. Mood alteration, either as 
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induction of euphoria or self-treatment of depression symptoms, was reported as a motivation of 
illicit GHB use (Sumnall et al., 2008). Potential antidepressant effects of the drug were reported in 
animal models (Zerbib et al., 1992) and early clinical studies (Tanaka et al., 1966; Rinaldi et al., 1967), 
but never evaluated in-depth according to present clinical trial standards. Consequently, the mood 
alteration in healthy subjects might be an indicator for a putative therapeutic effect in depressed 
patients, which we recently proposed because of the unique clinical and pharmacological profile of 
GHB (Bosch et al., 2012).  
 
At the behavioral level, GHB induced prosociality mostly in participants who showed low to 
moderate prosocial behavior under placebo. First, the drug increased the willingness to donate 
money in a charity donation task. Moreover, by trend, GHB increased the pleasure associated with 
donating money and reinforced the belief that the charity deserved the donation more strongly. This 
may be interpreted as an increase in altruism, which is conceptualized as giving up a value with no 
expectation of compensation. Interestingly, depressed patients show various impairments during 
social interactions, including both increased (Pulcu et al., 2014) and reduced altruism (Zhang et al., 
2012). While depression-related hyper-altruism was attributed to excessive feelings of guilt (Pulcu et 
al., 2014), increased altruism in our study participants appears to be rather pleasure- and 
compassion-related. Furthermore, GHB induced a tendency towards prosocial money distributions in 
our Social Value Orientation (SVO) task, reflecting an increased preference for fairness. Although SVO 
is commonly viewed as a personality trait, it is also susceptible to pharmacological modulations as 
shown in drug challenge studies using MDMA (Hysek et al., 2014).  
 
Finally, positive reciprocity was only slightly increased in the post-acute phase without reaching 
significance, but subjects again experienced significantly more pleasure during prosocial decisions. 
This might be in line with the so called “warm glow” hypothesis assuming that individuals experience 
pleasure during prosocial behavior, an effect which has been linked to activity of the mesolimbic 
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reward system (Phan et al., 2010). GHB seems to have effects on mesocorticolimbic dopaminergic 
pathways, which are controversially discussed, as the drug has both addictive and anti-craving 
properties (Keating, 2014). A recent translational model described an enhancement of mesolimbic 
pathway activity after GHB intake, resulting from a converging disinhibition of dopaminergic 
projections from the VTA to the nucleus accumbens and prefrontal cortex (Snead and Gibson, 2005). 
In this regard, the GHB-induced prosociality might be the behavioral correlate of a disinhibited 
mesolimbic reward system, which increases the sensitivity for hedonia-associated cues. As reaction 
time and memory performance remained unaffected by the drug, general impairment of task 
performance as a reason for increased prosociality can be ruled out. Considering the relatively short 
half-life of GHB of about 40 minutes (Abanades et al., 2006), together with the plasma concentration 
curve assessed in our subjects (Figure 1), it is possible that the decreasing GHB concentrations might 
explain the decreasing prosocial effects across tasks (Charity Donation > SVO > Reciprocity task).  
 
Currently, there are only few pharmacologic compounds with documented prosocial activity. In 
several studies, oxytocin was shown to facilitate prosocial behavior  including increased charity 
donations (van Ijzendoorn et al., 2011). Recently, MDMA was shown to have empathy-enhancing and 
prosocial effects, which were paralleled by an increase of oxytocin plasma levels (Schmid et al., 
2014). In contrast, in another study with MDMA-experienced individuals, the drug enhanced 
emotional empathy, while cognitive empathy, trust and reciprocity remained unaffected. 
Interestingly, neither oxytocin plasma levels nor exogenously applied oxytocin affected those 
measures (Kuypers et al., 2014).  GHBs’ most widespread street name is “liquid ecstasy”, as it is 
reported to share MDMAs empathogenic and prosocial effects (Uys and Niesink, 2005). However, 
both drugs differ strongly regarding their pharmacodynamic profile. While MDMA is a serotonin and 
noradrenalin releaser, the pharmacological effects of GHB are primarily mediated by GABAB receptor 
stimulation and secondary dopaminergic modulation (Uys and Niesink, 2005), or yet unknown 
mechanisms. Contrary to MDMA (Hysek et al., 2014; Schmid et al., 2014), GHB had neither 
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empathogenic effects such as increasing complex emotion recognition, emotional empathy, and 
mental perspective-taking in our social cognition tasks, nor were oxytocin plasma levels affected in 
our study. However, as oxytocin plasma levels do not fully reflect central oxytocin release (Neumann, 
2007), and GHB was shown to up-regulate hypothalamic oxytocin mRNA in rats (van Nieuwenhuijzen 
et al., 2010), at least centrally restricted involvement of oxytocin regarding the prosocial effects of 
GHB cannot be ruled out. Four reasons led to our hypothesis that the androgen system might be 
involved in the prosocial effects of GHB:  the drug seems to enhance sexually connoted affiliative 
behavior, alters levels of several steroid hormones, GABA-B receptors are discussed in the regulation 
of testosterone secretion (Amikishieva, 2007), and testosterone is a sex steroid hormone that might 
be a mediator of prosocial effects (Eisenegger et al., 2010). However, we did not observe any 
alterations of testosterone (and DHEA) levels in our subjects and hence conclude that GHB-related 
prosocial effects do not operate via the androgen system. 
 
Interestingly, GHB-induced neuroendocrine changes were limited to an increase in progesterone 
release here. Progesterone is a steroid hormone primarily synthesized in the testicles and the 
adrenal glands in males. However, small amounts are also synthesized in the brain, there targeting 
and influencing neuronal activity, which qualifies it as a neurosteroid (Guennoun et al., 2015). Animal 
and human data show that progesterone release mirrors an individual`s level of social affiliative 
motivation (Frye et al., 2000; Maner et al., 2010). For example, affiliative behavior of female rats is 
most pronounced, when progesterone release peaks during the estrous cycle (Frye et al., 2000). In 
humans, the desire to affiliate with others correlates positively with basal progesterone levels (Wirth 
and Schultheiss, 2006), and endogenous fluctuations of the hormone reflect fluctuations of female 
social-affiliative motivations during the menstrual cycle (Schultheiss et al., 2003). Moreover, 
interpersonal closeness increased salivary progesterone in a sample of 160 female college students, 
which predicted altruistic motivations one week later (Brown et al., 2009). Finally, in subjects with 
high rejection sensitivity, experimental social rejection can lead to heightened progesterone release 
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when given an opportunity to reaffiliate, which might reflect a desire for compensatory closeness 
(Maner et al., 2010). These studies support the notion that progesterone release might be a 
neuroendocrine mechanism that contributes to the prosocial effects of GHB. Although, we did not 
find direct correlations of progesterone levels and behavioral parameters, which might be due to the 
small sample size, our finding that GHB provoked prosocial behavior specifically in individuals with 
low progesterone levels strongly supports this relationship. 
 
Moreover, progesterone is a precursor of the other neurosteroids tetrahydroprogesterone (3α,5α-
THP) and tetrahydrodeoxycorticosterone (THDOC), which are both GABAA receptor agonists and 
studied as experimental therapeutics in stress-related disorders such as anxiety and depression 
(Zorumski et al., 2013). In animals, GHB leads to a dose-dependent increase of progesterone, 3α,5α-
THP and THDOC in the central nervous system, which significantly contribute to the sedative effects 
of the drug (Barbaccia et al., 2005). Moreover, central and peripheral increase of neurosteroid 
plasma levels were closely related (Barbaccia, 2004), thus implicating increased progesterone 
concentration to be a relevant marker of central neurosteroidogenesis.  
Another clinical aspect arises regarding GHB-induced progesterone release: GHB is used for the 
treatment of alcohol withdrawal and as an anti-craving agent (Keating, 2014), while some studies 
also point to anti-craving and relapse preventing effects of progesterone in nicotine (Lynch and 
Sofuoglu, 2010) and cocaine addiction (Yonkers et al., 2014). Therefore, increased progesterone 
release might contribute to the therapeutic effect of GHB in alcohol withdrawal and abstinence 
maintenance. 
In our subjects, stress hormones such as ACTH, cortisol, and aldosterone plasma levels remained 
unchanged. Previous studies indicate bidirectional effects of GHB on stress hormone release, 
depending on the initial activity of the HPA axis: increase at rest (Van Cauter et al., 1997), reduction 
in stressful conditions (Nava et al., 2007). The fact that stress hormone concentrations were not 
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increased under placebo suggests that our participants performed the tasks within a 
psychophysiologically balanced experimental setting. 
 
Nevertheless, the present study has some limitations. First, we only report a single dose of GHB (20 
mg/kg). However, when we evaluated a higher dose (35 mg/kg) we observed intense sedative effects 
and induction of nausea in several subjects, which strongly impaired test performance. Second, GHB 
is likely a “dirty drug”, acting on distinct neurotransmitter and neuroendocrine systems, thus 
complicating the interpretation of the results at a molecular level. Third, due to small sample size, 
the prosocial effects but also the lack of effect in some hormones and tasks have to be considered as 
preliminary and should be replicated in larger studies. Fourthly, we included only male subjects to 
avoid controlling for hormonal fluctuations due to menstrual cycle in women.  
 
In summary, the primary finding of this study is that GHB enhances mood and induces prosocial 
behavior in healthy subjects paralleled by an increase in progesterone release but without affecting 
oxytocin and testosterone plasma levels. The study thus confirms recreational GHB users´ self- 
reported effects on prosociality on an objective, experimental level. Mood enhancement and 
potentially increased neurosteroidogenesis make GHB an interesting experimental therapeutic agent 
to treat forms of depression and anxiety. On the other hand, the prosociality observed may be 
elicited by a direct activation of the mesolimbic reward system due to GHB- and/or GABAB receptor 
stimulation and/or indirectly due to increased progesterone secretion. Recently, arbaclofen, another 
GABA-B agonist with prosocial effects, has been suggested as new treatment for autism spectrum 
disorders (Insel, 2012). The clinical use of GHB as a means to improve interpersonal contact was 
noted early on in studies showing an improvement of patient-doctor alliance (Danon-Boileau et al., 
1962). Thus, the prosocial compound GHB might be useful to increase social engagement in patients 
with autism spectrum disorders or depression.   
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Table 1: Neuropsychological test performance under placebo and GHB (means and SD). MASC: Movie for the 
Assessment of Social Cognition, MET: Multifaceted Empathy Test, RTI: Reaction Time (CANTAB), DMS: 
Delayed Matching to Sample (CANTAB), RAVLT: Rey Auditory Verbal Learning Test. 
    Placebo GHB t df p Cohens dz 
MASC* Correct answers 34.9 33.6 1.67 13 0.12 0.45 
 
(sum) (3.6) (3.9) 
    
 
Correct control items 4.6 4.9 -1.59 13 0.14 0.42 
 
(sum) (1.2) (0.9) 
    
 
Recognition of emotions 73.3 71.4 0.59 13 0.57 0.16 
 
(%) (14.3) (14.2) 
    
 
Recognition of thoughts 85.7 76.8 1.44 13 0.17 0.38 
 
(%) (18.9) (20.7) 
    
 
Recognition of intentions 71.9 72.4 -0.14 13 0.89 0.04 
  (%) (10.2) (6.3)         
MET Cognitive Empathy  25.0 24.3 0.75 15 0.47 0.19 
 
(correct items) (4.5) (4.5) 
    
 
Explicit Emotional Empathy 5.1 5.0 0.67 15 0.51 0.17 
 
(mean rating) (1.3) (1.4) 
    
 
Implicit Emotional Empathy 4.5 4.5 -0.04 15 0.97 0.01 
 
(mean rating) (1.3) (1.5) 
    
 
Mean reaction time  3965 3728 0.84 15 0.41 0.21 
  (ms) (1053) (682)         
RTI Simple reaction time 275 276 -0.08 15 0.94 0.02 
 
(ms) (43.4) (47.7) 
    
 
Simple movement time 279 280 -0.24 15 0.82 0.06 
 
(ms) (64.9) (71.9) 
    
 
Simple accuracy 14.6 14.7 -0.37 15 0.72 0.09 
 
(score) (1.1) (0.7) 
    
 
5-choice reaction time 301 299 0.38 15 0.71 0.09 
 
(ms) (49.7) (49.7) 
    
 
5-choice movement time 282 279 0.69 15 0.50 0.19 
 
(ms) (65.5) (69.1) 
    
 
5-choice accuracy score 14.9 14.6 0.89 15 0.39 0.28 
  (score) (0.3) (1.1)         
DMS Correct simultaneous 4.8 4.9 -0.81 15 0.43 0.20 
 
(sum) (0.5) (0.3) 
    
 
Correct all delays 13.1 13.2 -0.10 15 0.92 0.02 
  (sum) (1.5) (1.7)         
RAVLT Immediate recall 9.3 10.1 -1.65 15 0.13 0.41 
 
(number of words) (1.9) (2.4) 
    
 
Delayed recall 7.1 7.8 -1.55 15 0.14 0.39 
 
(number of words) (2.1) (2.5) 
    
 
Recognition 0.88 0.90 -0.65 15 0.52 0.16 
  (p(A)) (0.1) (0.1)         
*Due to technical problems with the MASC, only data from 14 subjects were available. 
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Table 2: Area under the curve (AUC) of hormones under placebo and GHB (means and SD). ACTH: 
Adrenocorticotrophic hormone, AUC: Area under the curve, corr: corrected, DHEA: 
Dehydroepiandrosterone.  
         Placebo GHB t df p Cohens dz 
ACTH AUC  132.4 133.0 -0.07 14 0.95 0.02 
(4 time points) (41.2) (34.4) 
    ACTH_corr AUC -44.0 -15.0 -0.94 14 0.36 0.24 
(4 time points) (109.4) (44.5) 
    Oxytocin AUC 46.0 32.3 1.53 14 0.15 0.40 
(4 time points) (53.5) (30.7) 
    Oxytocin_corr AUC -7.0 -2.7 -0.18 14 0.86 0.05 
(4 time points) (84.7) (45.3) 
    Testosterone AUC 72.3 74.5 -0.75 15 0.47 0.19 
(6 time points) (14.8) (19.1) 
    Testosterone_corr AUC 3.7 2.6 0.63 15 0.54 0.16 
(6 time points) (6.7) (8.9) 
    Progesterone AUC 1.11 1.20 -0.88 15 0.39 0.22 
(6 time points) (0.44) (0.63) 
    Progesterone_corr AUC -0.14 0.03 -1.81 15 0.09 0.45 
(6 time points) (0.22) (0.40) 
    Aldosterone AUC 32.8 32.0 0.68 15 0.51 0.17 
(6 time points) (7.0) (5.1) 
    Aldosterone_corr AUC -7.7 -9.1 0.78 15 0.45 0.20 
(6 time points) (5.7) (8.0) 
    DHEA AUC 151.0 161.4 -1.52 15 0.15 0.38 
(6 time points) (33.9) (44.3) 
    DHEA_corr AUC -1.0 -15.8 1.71 15 0.11 0.43 
(6 time points) (16.2) (35.6) 
    Cortisol AUC 1164.5 1192.7 -0.32 15 0.76 0.08 
(6 time points) (311.8) (375.7) 
    Cortisol_corr AUC -392.3 -519.2 1.03 15 0.32 0.26 
(6 time points) (408.8) (464.8)         
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Figures  
Fig. 1: GHB plasma (means and SEM) concentration (a), and visual analogue scales (VAS) general drug 
effect (b), sedation (c), stimulation (d), and dizziness (e) after GHB and placebo 
administration. Paired t-tests: *p<.05, **p<.01, ***p<.001. 
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Fig. 2: Baseline corrected ratings (means and SEM) of the items disinhibition (a), euphoria (b), 
tendency to talk (c) and vitality (d) of the GHB specific questionnaire (GSQ). The values 
represent changescores from baseline (t-10min) on the respective test day. Paired t-tests: 
*p<.05, **p<.01. 
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Fig. 3: Prosocial behavior measures under GHB and placebo (means and SEM): Money donated in the 
Charity Donation Task (a), and Social Value Orientation (SVO) angle (b), and points given to 
the other player in the Reciprocity Task (c). Paired t-tests: *p<.05. 
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Fig. 4: Progesterone plasma concentrations (means and SEM) corrected for individual baseline (-
20min) levels on each test day (a) and baseline-corrected DHEA plasma levels (b). Paired t-
tests: (*)p<.10, *p<.05. 
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SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTARY METHODS 
 
Social Value Orientation 
Mean allocations for self and others were calculated for the primary SVO slider items. The subjects 
SVO index was then calculated from the inverse tangent of the ratio of the two mean allocations for 
self and the other from the primary items. The subjects’ SVO index is gained through an angle, which 
is produced by the inverse tangent of these two means. 
 
Reciprocity Task 
In this task, a virtual player A delegates, in three out of five instances, a decision about the 
distribution of money to another subject, player B. Player A thus either choses the status quo, i.e. 
keeping 20 points and leaving 20 points to player B, or trust player B by delegating the decision about 
the distribution of money to him/her. Delegating the decision will add 20 points to the total amount 
of distributable points. Being trusted, player B can either betray player A in keeping 55 points and 
giving 5 back, or show positive reciprocity in giving back 30, and keeping 30 points. 
 
Multifaceted Empathy Test 
To measure cognitive empathy (CE) subjects are asked to infer the mental state of a given person in a 
photograph and choose which of four words provided along with the picture describes best what the 
person in the picture is feeling. Explicit emotional empathy (EEE) is assessed by ratings of empathic 
concern (“How concerned are you for this person?”) on a visual-analogue scale within a range of 1-9 
(1=not concerned to 9=very concerned) while viewing the photograph. Implicit emotional empathy 
(IEE) is measured analogously by arousal ratings (“How calm/aroused does this picture make you 
feel?”, 1=very calm to 9=very aroused).  
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Movie for the Assessment of Social Cognition 
The film interrupts briefly for 45 times to ask questions about the actors’ feelings, thoughts, and 
intentions (“How is Michael feeling?”). In detail, the MASC asks 15 questions demanding the 
interpretation of emotions, 14 questions for intentions, and 4 questions for measuring thoughts. 
These questions are asked in a multiple-choice format with one correct answer and three distractors 
reflecting three different types of mistakes: a) insufficient mental state inferences (undermentalizing: 
reduced ToM), b) excessive (overmentalizing), and c) non-mental state inferences (physical 
causation, no-ToM). Therefore, the MASC provides a sum score for the errors and three subscales for 
different error types. To control for non-social inference, memory, and general comprehension 
effects, six control questions referring to physical events instead of a character’s mental state are 
asked during the test. In addition, the MASC allows for a separate quantification of the extent to 
which emotional mental states, thoughts, and intentions are inferred correctly. Both the MET and 
MASC were implemented in Presentation (Version 14.1, Neurobehavioral Systems, Albany, CA). 
 
Cognitive Tests 
Cambridge Neuropsychological Test Automated Battery (CANTAB): 
Delayed Matching to Sample (DMS): The DMS test was implemented at t+28 min. A stimulus 
consisting of a square with different patterns and colors was presented on the screen, which the 
subject had to memorize. Subsequently, four patterned squares were presented from which the 
subject had to recognize the one that was shown before. The test consists of 20 counter balanced 
trials of five simultaneous presentations of the stimulus and the recognition squares, as well as five 
trials of subsequent presentation with a delay time of 0 msec, 4000 msec and 12000 msec. The 
duration of the test is 6.5min. 
Reaction Time (RTI): The RTI test was implemented at t+52 min. Subjects had to push down a button 
until a yellow dot appeared in a circle on the screen (simple choice) or in one of five circles (5-
choice), which they then had to try to touch as fast and adequate. The five choice trials started if the 
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subject performed nine out of ten trials of the simple choice correctly. After nine of ten correctly 
performed trials, the test was stopped. Total duration of the task was about 5min. 
Verbal memory: 
A word list of 15 nouns (learning list) was presented once and subsequently participants were asked 
to recall as many words as possible (t+25min, immediate recall). Participants were then asked to 
recall the word list again 30min later (t+57min, delayed recall). After that a third list of 50 nouns 
including all words of the first list as well as 35 new, but semantically- and phonetically-related words 
were presented (t+58min, recognition,). The task yields the three dependent variables immediate 
recall, delayed recall, and adjusted recognition performance (p[A] according to (Forrester and Geffen, 
1991)]), whereas p(A) is comparable to the discrimination performance (d-prime) in signal detection 
theory (Green and Swets, 1966). 
 
Endocrine parameters and pharmacokinetics of GHB (Details) 
Two types of blood samples were collected: A) samples for the assessment of plasma GHB, 
testosterone, aldosterone, progesterone, DHEA, ACTH, and cortisol and B) samples for the 
assessment of oxytocin. Time points of sampling were t-20,+35,+60,+100,+135, and +190min. Blood 
for the assessment of oxytocin (B) was collected in 5 ml BD Vacutainer K2EDTA tubes for plasma 
(Vacutainer Systems, becton Dickinson, Plymouth, UK), while blood for the assessment of plasma 
GHB, testosterone, aldosterone, progesterone, DHEA, ACTH, and cortisol (A) was collected in 10 mL 
BD Vacutainer K2EDTA tubes for plasma (Vacutainer Systems, becton Dickinson, Plymouth, UK) and 
spiked with 1 mM PMSF solution in ethanol (to avoid enzymatic activity of serine proteases). Plasma 
was obtained approx. 3 h after blood collection by centrifugation at 1800 rpm (A) and 4000 rpm (B) 
for 10 min at 4°C. Blood samples were kept on ice until plasma generation. Plasma was stored at -
80°C prior the analysis. Prior to the analysis of GHB and the steroids, plasma was thawed inside the 
refrigerator at 6°C for 3-4 h. Then, an aliquot of 50 µL plasma was used for the analysis GHB by GC-
MS (see below) while an aliquot of 0.5 mL plasma was used for the analysis of bioactive lipids by LC-
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MS/MS according to (Gachet et al., 2014). Both analyses were performed in parallel. Plasma ACTH 
was analyzed using a commercially available ELISA kit for ACTH (IBL International, Hamburg, 
Germany). The analytical sensitivity was 0.22 pg/mL, intra-assay and interassay coefficients of 
variation were 7.1% (Nyuyki et al., 2012). 
 
Analysis of GHB in human plasma by GC-MS 
Materials 
GHB (Xyrem®) as analytical standards was purchased from UCB Pharma GmbH, Monheim, Germany. 
GHB-d6 (internal standard (IS)), HPLC-grade methanol, HPLC-grade acetonitrile (ACN), N,N-
dimethylformamide (DMF) and N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) were obtained from 
Sigma-Aldrich, Steinheim, Germany. Deionized water (18.2 MΩ x cm) was obtained from an ELGA 
Purelab Ultra Genetic system (VWS (UK) Ltd, ELGA LabWater, UK). 
 
Standard solutions  
Standard solutions used as calibrators were prepared in methanol covering a concentration range 
0.001 to 0.5 mg/mL. For constructing calibration curves and method performance analysis within the 
study, 10 or 20 µL of standard solutions were applied to plasma samples (instead of only methanol) 
and followed by sample preparation (see below) to reach the analytical range of 4.5 to 4500 pg on 
column. The calibration curve used for the analysis of plasma samples was build using 8 calibration 
points. A GHB-d6 solution of 0.2 µg/mL prepared in water was used as internal standard (IS)(i.e. 900 
pg on column). 
 
Sample preparation and GC-MS analysis 
The analysis of GHB was performed according to  Meyer et al. (2011) with slight modifications. In 
brief, 50 µL of plasma were added to a 2 mL Eppendorf containing 10 µL of IS, 50 µL ACN and 20 µL 
methanol (with [i.e. control and calibration samples] or without analytical standard). The mixture 
OG Bosch et al. 
36 
 
was vigorously vortexed and then centrifuged at 16,100 g at 4°C for 5 min. For derivatization, an 
aliquot of 20 µLof the supernatant was transferred to into conic amber vial and mixed with 20 µL 
DMF and 300 µL BSTFA. The vial was immediately closed, vortex and derivatized at 70°C for 15 min. 
After cooling, samples were analyzed by gas chromatography (GC) electron ionization (EI) mass 
spectrometry (MS) using an Agilent 6890 N GC equipped with a 30 m HP-5MS column and a 5975 C 
EI-MS with triple-axis detector. Helium was used as carrier gas at a flow rate of 1.3 mL/min. The inlet 
temperature was kept at 250°C and 1 µL of the sample was injected in splitless mode. The oven 
temperature program was as follows: initial temperature of 60°C (hold time 3 min), increased by 
10°C/min to 120°C, increased by 30°C/min to 280°C (hold time 15 min). Total analysis time 30min. 
The MS conditions were: Ionization energy 70eV, ion source temperature 230°C, MS Quant 
temperature 150°C and Aux temperature 280°C. Specific ions were used for selected ion monitoring 
(SIM). For the analysis of GHB, one target ion (m/z= 233) and two qualifier ions (m/z= 204 and 117) 
were used. For the analysis of GHB-d6, m/z=239 was used. The performance of the method was 
evaluated using external calibrations (i.e. spiking calibration solutions [see standard solutions] into 
plasma and processing as stated above [n=3]) and control samples. The results were analyzed based 
on the peak area ratio between analyte and IS. All the calibration curves had a correlation coefficient 
(R2) better than 0.999. The inter-day variation coefficient (CV) was bellow to 10% and accuracy was 
between 90 and 115%. The recovery of control samples was in the range of 90-100%.  
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Supplementary Table 1: List of charities used in the Charity Donation Task and percentage of 
individuals donating and total amount donated in Swiss francs (CHF) under placebo and GHB 
(without exclusion of subjects highly prosocial under placebo). 
 
Charity % CHF 
Placebo GHB Placebo GHB 
Gesellschaft für bedrohte Völker (Society for Threatened  
Peoples) 
18.8 18.8 65 75 
Médecins Sans Frontiers (Doctors Without Borders) 12.5 18.8 30 65 
Schweizerisches Rotes Kreuz (Swiss Red Cross) 12.5 6.3 55 20 
Stiftung für wissenschaftliche Forschung an der  
Universität Zürich (Foundation for Research in Science and  
the Humanities at the University of Zurich) 
12.5 6.3 45 10  
Kinderkrebshilfe Schweiz (Swiss Children’s Cancer Aid  6.3 18.8 15 55 
Swiss World Wide Fund For Nature (WWF) 6.3 12.5 15 35 
Greenpeace 0 0 0 0 
AIDS-Hilfe Schweiz (Swiss AIDS Federation) 0 0 0 0 
Brot für Alle (Bread For All) 0 0 0 0 
Amnesty International 0 0 0 0 
No donation 31.3 18.8 0 0 
Total Donation  68.7  81.2 225 260 
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Supplementary Figure 1: Flowchart of the study. Abbreviations: CANTAB, Cambridge  
Neuropsychological Test Automated Battery; DMS, Delayed Matching to Sample; GSQ, GHB Specific  
Questionnaire; MASC, Movie for the Assessment of Social Cognition; MET, Multifaceted Empathy  
Task; POMS, Profile of Mood States; RTI, Reaction Time; SADI, Sexual Arousal and Desire Inventory;  
VAS, Visual Analogue Scale; VLMT, Verbal Learning and Memory Test. *= data will be published  
elsewhere. 
 
Time point
t – 30 min
t – 25 min
t – 20 min
t – 17 min
t – 15 min
t – 13 min
t – 10 min
t0
t + 06 min
t + 25 min
t + 28 min
t + 35 min
t + 38 min
t + 40 min
t + 41 min
t + 50 min
t + 52 min
t + 57 min
t +  60 min
t +  63 min
t + 66 min
t + 68 min
t + 70 min
t + 75 min
t + 90 min
t + 100 min
t + 102 min
t + 104 min
t + 106 min
t + 109 min
t + 120 min
t + 135 min
t + 138 min
t + 141 min
t + 150 min
t + 163 min
t + 182 min
t + 183 min
t + 190 min
t + 198 min
t + 225 min
Experimental Session
Task
Urine test
IV-catheter
Blood sample 1 / Vital signs*
GSQ 1
VAS 1
POMS 1*
SADI 1*
GHB / Placebo application
Pause
VLMT 1
CANTAB/ DMS
Blood sample 2 / Vital signs*
GSQ 2
VAS 2
Sexual Arousal Task*
SADI 2*
CANTAB/ RTI
VLMT 2
Blood sample 3 / Vital signs*
VAS 3
GSQ 3
POMS 2*
Charity Donation 
MET
Social Value Orientation
Blood sample 4 / Vital signs*
SADI 3*
GSQ 4
VAS 4
MASC
Blood sample 5 /  Vital signs*
GSQ 5
VAS 5
POMS 3
SADI 4
Reciprocity task
GSQ 6
VAS 6
POMS 4*
Blood sample 6 / Vital signs*
End of Session
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Supplementary Figure 2: GSQ Scores GHB vs. placebo A) silliness, B) happiness, and C) sexual arousal,  
and D) sensitivity to sound. 
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Supplementary Figure 3: Correlations of feeling of pleasure when being prosocial under placebo (r=-
.30, p=.29) A), and under GHB (r=-.65, p=.008) B) in the reciprocity task. 
A) 
 
B) 
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Supplementary Figure 4: Plasma levels under GHB vs. placebo of A) DHEA uncorrected (drug: p=.1, 
time: p=.3, drug*time: p=.2) , B) DHEA baseline-corrected (drug: p=.1, time: p=.3, drug*time: p=.2), C) 
ACTH uncorrected (drug: p=.79, time: p=.07, drug*time: p=.46), D) ACTH baseline-corrected (drug: 
p=.36, time: p=.07, drug*time: p=.46), E) Oxytocin uncorrected (drug: p=.25, time: p=.54, drug*time: 
p=.89), F) Oxytocin baseline-corrected (drug: p=.81, time: p=.62, drug*time: p=.85), G) Testosterone 
baseline uncorrected (drug: p=.39, time: p<.01, drug*time: p=.16), H) Testosterone baseline-
corrected (drug: p=.64, time: p<.001, drug*time: p=.17), I) Aldosterone uncorrected (drug: p=.60, 
time: p<.001, drug*time: p=.73), J) Aldosterone baseline-corrected (drug: p=.47, time: p<.001, 
drug*time: p=.73), K) Cortisol uncorrected (drug: p=.62, time: p<.001, drug*time: p=.60), L) Cortisol 
baseline-corrected (drug: p=.31, time: p<.001, drug*time: p=.60). Paired t-tests: (*)p<.10, **p<.01. 
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